Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 38 of 46 for:    SIR-Spheres

Predictive Value of 99mTc- Albumin Spheres Before 90Y- SIR Therapy (EXPLOSIVE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01186263
Recruitment Status : Completed
First Posted : August 23, 2010
Last Update Posted : September 4, 2014
Sponsor:
Collaborator:
Sirtex Medical
Information provided by (Responsible Party):
Jens Ricke, University of Magdeburg

Brief Summary:
The purpose of this study is to assess the predictive value of 99mTechnetium (Tc)- labeled albumin in macroaggregates (MAA) and in microspheres (B20) injected into the common hepatic artery for the distribution of 90Yttrium- Selective Internal Radiotherapy (SIRT)-spheres (SIR- spheres).

Condition or disease Intervention/treatment Phase
Colorectal Cancer Liver Metastases Drug: MAA for diagnostic SPECT imaging Drug: Diagnostic B20- SPECT imaging. Phase 2

Detailed Description:
Patients with metastases of colorectal tumors will be included into this study provided that they are scheduled for 90Y SIR spheres therapy for clinical reasons. Before 90Y SIR spheres therapy, patients will receive a diagnostic examination with injection of MAA (group A) or B20 (group B) into the common hepatic artery to rule out a relevant shunt volume to the lung or other extra-hepatic locations (e.g., stomach) as recommended by the manufacturer. After the diagnostic scan, therapy with SIR- spheres will be conducted in 2 separate sessions with selective injection of 90Y labeled SIR spheres into the right and left hepatic artery at two separate occasions (routine procedure at the University of Magdeburg, Germany). In addition, therapeutic sessions will include the selective injection of MAA or B20 into the right / left hepatic artery according to a predefined plan (either alone or as a mixture with the SIR spheres).The intra-hepatic distribution of 90Y labeled SIR spheres will be assessed using "Bremsstrahlen"- Single- Photon- Emission- Computed- Tomography (SPECT)- imaging, the distribution of MAA and B20 will be assessed using SPECT imaging.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 24 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Diagnostic
Official Title: Exploratory Study to Assess the Predictive Value of 99mTc-labeled Albumin Spheres for the Intrahepatic Distribution of 90Y SIR Spheres in Patients With Liver Metastases of Colorectal Tumors
Study Start Date : July 2010
Actual Primary Completion Date : July 2011
Actual Study Completion Date : August 2013

Arm Intervention/treatment
Experimental: 99mTc- labeled albumin macroaggregates (MAA)
Diagnostic MAA- SPECT- imaging.
Drug: MAA for diagnostic SPECT imaging
Intraarterial application of 5ml containing 500.000 particles with an activity of 150MBq.
Other Name: TechneScan Lyo MAA

Experimental: 99mTc- labeled albumin microspheres (B20)
Diagnostic B20- SPECT- imaging.
Drug: Diagnostic B20- SPECT imaging.
Intraarterial application of 5ml containing 150.000 particles with an activity of 150 MBq.
Other Name: ROTOP HSA microspheres B20




Primary Outcome Measures :
  1. Percentage of liver volume for which the accumulation of SIR spheres was correctly predicted by the preceding Tc-99m MAA scintigraphy [ Time Frame: Tc-99m MAA scan one day prior to radioembolisation; Bremsstahlen-Scan after SIR spheres therapy ]
    The percentage in liver volume for which the accumulation of SIR spheres during therapy was correctly predicted by Tc-99m MAA will be given by a blinded reader in categories by visual assessment (0-10%, >10-20%, >20-30%, …, >90-100%) (only patients who received Tc-99m MAA during evaluation.)


Secondary Outcome Measures :
  1. Percentage of liver volume for which the accumulation of SIR spheres was correctly predicted by the preceding Tc-99m B20 scintigraphy [ Time Frame: Tc-99m B20 scan one day prior to radioembolisation; Bremsstahlen-Scan after SIR spheres therapy ]
    The percentage in liver volume for which the accumulation of SIR spheres during therapy was correctly predicted by B20 will be given by a blinded reader in categories by visual assessment (0-10%, >10-20%, >20-30%, …, >90-100%) (only patients who received Tc-99m B20 during evaluation.)

  2. Pharmacokinetic parameters of the intrahepatic distribution of MAA and B20. [ Time Frame: One day prior to SIRT ]
    elimination half-life calculated in [min] from the decay-corrected radioactivity concentration measured over the liver; % radioactivity trapped in the liver at the individual measuring time points (of total radioactivity measured over the liver in the first scan); percent lung shunt (percentage of liver activity leaking to the lung at the individual time points)

  3. Adverse events as elicited upon indirect questioning. [ Time Frame: At any visit. ]
    Number of patients with adverse events (AEs), number of AEs per patient; descriptive listing of all AEs



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • age: between 18 and 85 years
  • if female, postmenopausal or surgically sterilized
  • liver metastases of a colorectal tumor in both liver lobes
  • scheduled for therapy with 90Y SIR spheres for clinical reasons
  • life expectancy longer than 6 months
  • willing and able to undergo all study procedures
  • having voluntarily provided written and fully informed consent

Exclusion Criteria:

  • presenting with a contraindication to 90Y SIR spheres therapy
  • variants of the arterial hepatic blood supply which interfere with the objectives of this study (e.g., variants of Michel)
  • women who are pregnant, lactating or who are of childbearing potential
  • patients being clinically unstable
  • uncooperative, in the investigator's opinion
  • any contraindication to SIRT treatment
  • any concomitant chemotherapy
  • shunt to the lung >10%
  • shunt to any extrahepatic organ (except the lung)
  • having been previously enrolled in this study
  • participating in another prospective clinical trial

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01186263


Locations
Layout table for location information
Germany
Clinic for Radiology and Nuclear Medicine
Magdeburg, Sachsen-Anhalt, Germany, 39120
Sponsors and Collaborators
University of Magdeburg
Sirtex Medical
Investigators
Layout table for investigator information
Principal Investigator: Jens Ricke, Prof. Dr. University of Magdeburg, Faculty for Medicine

Layout table for additonal information
Responsible Party: Jens Ricke, Prof. Dr., University of Magdeburg
ClinicalTrials.gov Identifier: NCT01186263     History of Changes
Other Study ID Numbers: RAD050
2008-005609-21 ( EudraCT Number )
First Posted: August 23, 2010    Key Record Dates
Last Update Posted: September 4, 2014
Last Verified: September 2014
Keywords provided by Jens Ricke, University of Magdeburg:
liver metastases
MAA
B20
SIR spheres
SPECT
intra-hepatic distribution
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasm Metastasis
Liver Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Digestive System Diseases
Neoplastic Processes
Pathologic Processes
Liver Diseases